20/20 HealthCare Partners

20/20 HealthCare Partners LLC, founded in 2005, is a Massachusetts-based global investment group specializing in early-stage technology and life science innovation within the healthcare industry. With a focus on creating value through strategic advice, team building, and syndicated investment, the firm partners with entrepreneurs and executives to build valuable companies that impact healthcare and improve quality of life. In addition to growth equity and buyout investments, 20/20 HealthCare Partners also provides assistance with strategic alliances, company mergers, and operational support, aiming to support innovative companies in biotechnology, pharmaceuticals, healthcare industry software, diagnostic imaging, medical devices, and healthcare IT.

Hillel Bachrach

Managing Partner

Christine Bunt

Partner

Martin D. Mann

Partner

17 past transactions

Verseau Therapeutics

Private Placement in 2019
Verseau is creating a new class of therapeutics, macrophage checkpoint modulators, to benefit patients with cancer, immune and inflammatory diseases. The company's modulators identify novel targets and develop therapies that shift macrophages between immune activators and silencers in disease, enabling physicians to benefit patients from immunotherapy.

Coagulo Medical Technologies

Venture Round in 2020
Coagulo Medical Technologies, Inc. develops testing systems that detects, identifies, and quantifies the effect of all anticoagulants in whole blood and communicates actionable results to healthcare providers. The company is based in Auburndale, Massachusetts.

EightSpokes

Venture Round in 2015
EightSpokes, Inc. offers a SaaS platform that solves the problem of launch delays by implementing the Enlighten launch management software to replace the manual planning, coordination, and communication problems that occur. The company was incorporated in 2012 and is based in Lexington, Massachusetts.

QBotix

Series A in 2012
A solar panel that tracks the sun throughout the day produces up to 30% more electricity than one that does not. Solar project developers install single-axis tracking for most utility-scale sites, balancing upfront costs versus electricity revenues to maximize rates of return. QBotix disrupts today's cost curve of fixed-tilt, single-axis tracking, and dual-axis tracking with an innovative tracking solution that offers dual-axis tracking at single-axis price. This reduces the levelized cost of energy by 10-20% while providing the added benefit of higher reliability and system intelligence.

EnClear Therapies

Private Placement in 2020
EnClear Therapies, Inc. develops device-based therapies for the treatment of neurodegenerative disease. The company delivers and monitors cerebrospinal fluids (CSF). The company’s therapeutic platform focuses on removing toxic proteins from the CSF. Its products are targeted for patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP) and other conditions related to the central nervous system (CNS). EnClear Therapies, Inc. was incorporated in 2018 and is based in Newburyport, Massachusetts.

Velocomp

Venture Round in 2011
Velocomp is a sports technology company that offers a range of power measurement tools for bicycles worldwide. Its products include iSport, a wireless cycling computer and power meter; iPro, a product which helps in tracking progress and analyzing rides; iBike POWERHOUSE, a cycling computer that automatically adjusts to exercise goals; iAero, a product which helps in power and wind tunnel measurements; iDash CC, a cycling computer; iDash CC Deluxe, a fitness computer; iDash +Power, a dashboard for training and fitness; and protective bicycle cases and mounts for iPhone and iPod touch.

Variantyx

Series C in 2022
Variantyx Inc. provides whole genome sequencing based diagnostic testing platform. It performs diagnostic testing for rare disorders with genome unity, personal genome screening for healthy individuals with genomic inform, and Next Generation Sequencing (NGS) analysis and reporting for laboratories with genomic intelligence. Variantyx Inc. was founded in 2014 and is headquartered in Framingham, Massachusetts.

Physiq

Venture Round in 2013
physIQ has developed a personalized physiology analytic platform (PPA) for use in both the regulated healthcare market as well as the unregulated health and fitness market. The technology is designed to detect subtle changes in vital signs and other health indicators to help clinicians manage patients with chronic illness, and to help consumers track their own health and fitness levels. The key differentiator between the physIQ platform and other technologies is that it constructs a personalized baseline norm for each person monitored, rather than simple trending or comparison to population-based statistics. Our technology can also be embedded into patient monitoring devices from other manufacturers who are seeking to design "smarter" products.

Variantyx

Series C in 2021
Variantyx Inc. provides whole genome sequencing based diagnostic testing platform. It performs diagnostic testing for rare disorders with genome unity, personal genome screening for healthy individuals with genomic inform, and Next Generation Sequencing (NGS) analysis and reporting for laboratories with genomic intelligence. Variantyx Inc. was founded in 2014 and is headquartered in Framingham, Massachusetts.

SQZ Biotech

Series A in 2015
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.

XRHealth

Private Placement in 2020
XRHealth Ltd. develops medical virtual reality (VR) software solutions. The company offers VRPhysio, a digital healthcare platform for offering virtual reality based physical therapy; VRPhysio Home, a solution that enables patients to be instructed to carry out physical therapy workout for treatment and prevention of skeletomuscular injuries; VRReliever, a platform for management of nociceptive and neuropathic pain by creating distractions in their environment; VRCogni, a virtual reality solution that offers therapeutic activity to improve motor function in stroke victims, as well as in patients with alzheimer’s and dementia; VRPsyc, a software to provide exposure therapy for mental disorders, including general stress, phobias and anxieties, eating disorders, and post-traumatic stress disorder (PTSD); and VRCoordi, a solution to improve and recover coordination skills for patients suffering from parkinson’s, brain injury, developmental coordination disorder (DCD), and autism. The company caters to patients, clinicians, and other healthcare professionals. XRHealth Ltd., formerly known as, VR Health Ltd was founded in 2016 and is based in Tel Aviv, Israel.

Zixi

Venture Round in 2011
Zixi is the leading enabler of flawless broadcast quality HDTV over the Internet. Broadcasters, enterprises and video-on-demand services use Zixi to enrich user experience, create new services and significantly reduce costs. Zixi enables the delivery of live and on-demand HD video content over the Internet in real time and with unprecedented quality. The technology is applicable for multi-media delivery and consumption across a spectrum of industries.

EnClear Therapies

Series A in 2020
EnClear Therapies, Inc. develops device-based therapies for the treatment of neurodegenerative disease. The company delivers and monitors cerebrospinal fluids (CSF). The company’s therapeutic platform focuses on removing toxic proteins from the CSF. Its products are targeted for patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP) and other conditions related to the central nervous system (CNS). EnClear Therapies, Inc. was incorporated in 2018 and is based in Newburyport, Massachusetts.

Coagulo Medical Technologies

Private Placement in 2020
Coagulo Medical Technologies, Inc. develops testing systems that detects, identifies, and quantifies the effect of all anticoagulants in whole blood and communicates actionable results to healthcare providers. The company is based in Auburndale, Massachusetts.

Verseau Therapeutics

Venture Round in 2019
Verseau is creating a new class of therapeutics, macrophage checkpoint modulators, to benefit patients with cancer, immune and inflammatory diseases. The company's modulators identify novel targets and develop therapies that shift macrophages between immune activators and silencers in disease, enabling physicians to benefit patients from immunotherapy.

Variantyx

Venture Round in 2023
Variantyx Inc. provides whole genome sequencing based diagnostic testing platform. It performs diagnostic testing for rare disorders with genome unity, personal genome screening for healthy individuals with genomic inform, and Next Generation Sequencing (NGS) analysis and reporting for laboratories with genomic intelligence. Variantyx Inc. was founded in 2014 and is headquartered in Framingham, Massachusetts.